Glucagon-like Peptide-1 Receptor Agonists And Pancreatitis And/or Pancreatic Cancer Risk In T2DM:a Systemic Review And Meta-analysis

Objective: The aim of this meta-analysis was to review systematically the association of GLP-1RAs with pancreatitis and/or pancreatic cancer risk in type-2 diabetes mellitus.Methods: Databases including Pub Med,Embase,The Cochrane Library,CNKI,Wan Fang Data and CBM,were searched electronically for randomized controlled trials(RCTs)of GLP-1RAs in pancreatitis and/or pancreatic cancer risk in T2 DM patients up to Jan.2020.According to the inclusion and exclusion criteria,reviewer screened literatures extracted date,and assessed the methodological quality of the included studies.RCTs were eligible if they compared GLP-RA with placebo in T2 DM patients,and reported outcomes required for events of pancreatitis and/or pancreatic carcinoma.Then the Rev Man 5.4 software was used for meta-analysis.Results: Nine RCTs enrolling 61 610 patients with T2 DM were identified.A total of 168 cases of acute pancreatitis and 97 cases of pancreatic cancer were reported.The results showed that there were no significant differences between the GLP-1RA group and the control group,either in the pancreatic overall adverse events(RR=1.26,95%CI(0.99,1.61),P=0.06),pancreatitis(RR=1.19,95%CI(0.88,1.62),P=0.25)and pancreatic cancer(RR=1.26,95%CI(0.84,1.88),P=0.26).Conclusions: Pooled analysis of RCTs suggest that GLP-1RA treatment did not increase any risk of either pancreatitis or pancreatic carcinoma in T2 DM patients.However,long-term studies are needed to prove this conclusion.